A compound of formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a pharmaceutically acceptable salt thereof, ** Formula ** in which X is selected from the series consisting of>； = N - y>； = N (O) -； R1, R2 and R3 are independently selected from each other from the series consisting of hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkyl -O-, nitro, cyano, (C1-C4) alkyl -OC ( O) -, R4-N (R5) -C (O) - and R6-N (R7) -S (O) 2-； R4 is selected from the series consisting of hydrogen, (C1-C4) alkyl, cycloalkyl (C3-C7), cycloalkyl (C3-C7) -alkyl (C1-C4) -, phenyl, phenyl-alkyl (C1-C4) -, Het1 and Het1-(C1-C4) alkyl -, in which Het1 is optionally substituted with one or more identical or different R8 substituents； R5, R6 and R7 are independently selected from the series consisting of hydrogen, (C1-C4) alkyl, cycloalkyl (C3-C7) and cycloalkyl (C3-C7) -alkyl (C1-C4) -； R8 is selected from the series consisting of halogen, (C1-C4) alkyl, hydroxy, oxo, (C1-C4) -O- alkyl and cyano； R10 is selected from the series consisting of hydrogen, (C1-C4) alkyl, cycloalkyl (C3-C7), cycloalkyl (C3-C7) -alkyl (C1-C4) - and alkyl (C1-C4) -O-alkyl (C1-C4) -, with the proviso that R10 can only be hydrogen if X is>； = N (O) -； R11 is selected from the series consisting of (C1-C4) alkyl that is optionally substituted with one or more identical or different R12 substituents, cycloalkyl (C3-C7) that is optionally substituted with one or more identical or different R13 substituents, and Het2 which is optionally substituted with one or more identical or different R14 substituents and in which Het2 is linked by a ring carbon atom； or groups R10 and R11, together with the nitrogen atom that carries them, form a 4-membered 12-membered heterocycle, monocyclic or bicyclic, saturated or partially unsaturated which, in addition to the nitrogen atom carrying R10 and R11, comprises 0 , 1 or 2 additional ring heteroatoms selected from the series consisting of ni
